Paul. conference Hello, medical Chief morning Gruis, everyone, fourth Thanks, our and welcome Chief call. by our to our officer, quarter Kellen, Officer. this and Scott I'm joined Financial Kirsten
to this by FDA on off clinical like hold believe hold. on pivotal remove our resolution start ReMEDyX I'd the Phase work approach the and we updating will the the call with to be our communications final X/X clinical the today we everyone what trial as our status of of
the made that to a product by in switching up the ReMEDyX by of hold Phase our with was effects In half IV DMXXX retained bag the X issue Recall bag trial. the DMXXX, caused but our IV drug. candidate formulation new our from prior caused drug polyolefin was not ReMEDyX to trial, any of
up which Phase as ReMEDyX twice formulation, any pivotal not does the study effectively to bag trial, to X/X IV retain delivering our the new In we switched much PVC to participants. of DMXXX DMXXX
initial we hypertension limiting DMXXX. in significant pressure is that dose drops this clinically studies, tolerability or believe hypertension identified our three In what those blood a for caused transient the as participants. We safety
and is drops for pressure the active mechanism of DMXXX in result, at that the least DMXXX with are clearly a consistent believe blood events hypertensive that patients. action indicate in we As
to referred to October the world the significant In-Use compatibility as bag was was the meeting stimulate usage, expected had expand request requirements study need originally real to a clinical most FDA hold Their the that study. request Type We full letter. discuss for our which In study. FDA's A would to continue to IV an we with
we study. for only us one a However, for that we saved we're written Type are the use entitled their In-Use Type on In-Use our the requirements. December received this FDA, communication written expectations meeting Since A provided to to which from in meeting, from A a discussion pleased study having communication
we would for study study the In-Use and We the that incorporated protocol protocol into FDA believed the confirmation updated the the FDA's satisfy submitted that follow-up a with requirements. protocol the reasonable. Last our feedback request to that notification FDA month, indicating was the a protocol received
Part Part The the as DMXXX. varying a storage, bag is parts. duration, using In-Use temperatures simulates with actual being worst two scenarios tubing study one hospital and the light. tests two IV conducted in administer to pump case use in and such
conclusion prior of The the is our first from that In-Use part the reached this complete believe in and the part confirms testing. we study we data
X kg. in retained the earlier that revision up XX% used proposed to compared IV used per ReMEDyX approximately Specifically, ReMEDyX of was micrograms IV the DMXXX the the our the to supports as to ReMEDyX from it in confirmed and to per bags dose bags the in kg X.X from IV micrograms
submitted. a of confirmation issues request now two that been for have study of is the have all the feedback the the we addressed and FDA, submitted part clinical In-Use once hold results These to with along
occurring of conducting part in the In-Use once will study results, currently two April. we the and complete, which FDA, the are be to anticipate We submitted
we enhance the study in year for measuring developed learned a affect levels and and FDA dosing run and more were rates. In-Use our IV of and we while to preparing assay study KLKX. from levels study, not dose KLKX sensitive what assay on awaiting consistency the handling will procedures the measures activity feedback the the of In-Use In-Use protocol last the we year, the that two the likely Note for Late only that early this part
FDA We a chose to question do methods. existing this assay as our had the posed about
a to While might we were delay the the of complete reasonable, we ReMEDyX assays work existing believe our less and FDA prudent to and this questions further additional time trial. have decided in ultimately be consuming that resumption eliminate risk
asked of whether drops manufacturing and events ReMEDyX. or by cause also to The trypsin pressure. substance blood potential FDA trypsin in in use a This itself of contributor in the be from the likely the trypsin DMXXX hypotensive cause had question the could stems can
and February, Early not on-going testing to In development submitted manufacturing removed confirming that manufacturing the measurable DMXXX had FDA program, process. in DMXXX. testing least initiated at residue in there or as confirmed DMXXX detectable fully XXXX, the was that provided is that during we to assays part validated update This trypsin the the for not the no we of from trypsin methods in reports trypsin was review. to FDA our
that levels At appear I'm point, pleased this the feedback also assessment appropriate to say is good on-going dialogue their with the FDA. we our assays a we acceptable. received developed recently have that and We of believe trypsin
an the are response up and an will on clinical respond update of review ReMEDyX FDA XX is Once We receive hold. confident lifting sight timing a we the requesting their restarted. to clinical our we letter has for end to response, hold. in days expected provide appreciate we the the Note the engagement to that and to that getting complete
This XC have initiated of the IV also IV used in In-Use ascending study. decided starting study DMXXX trial. we of the requested open not PVC bags FDA, is on label, made in our before the was from Yesterday, the measure ReMEDyX we a a dosing the single dose part proactive Phase by that announced but
do two for We so to reasons. primary chose
Then sufficient the Phase basis First, for dose. adjusting levels the provided with achieved not ReMEDyX. study FDA results will is for conclusively going some levels of IV reason study dose concentration serum In-Use that of the results the their the demonstrate DMXXX XC proposed the IV forward in of satisfied the
reason confidence second do This will when in in our patient to commitment enrollment start driving demonstrates to has physician and we help the that resume hope study us ReMEDyX. with we investigators. strong safety and the The
Enrollment we in last available May. study began going should in XC the micrograms Phase gets preliminary complete first with week, to be the kg which data X.X in level April and forward use to us cohorts, dose three per propose
would also learned this a I cleared prepared process remarkably stronger to and a do the better and through so. and special time. and thank a clinical this initiated designed, period come of once by a to lot as DiaMedica We've will study resume in trial our activities give planned to you getting FDA team for result, recognize to like out short
is in management neurologist due in board XXXX. drug Officer, Medical small This medical drugs part approval. also with Kirsten bringing experience certified some several and team Gruis, Chief our is through no FDA to extensive to development additions in Dr. our key a practice in
our been the Chief leading Kirsten Officer. also has Dominic managing instrumental to Commercial in communications. the FDA our Cundari, response and
the for benefits his TPA recall of managed will to retirement and potential because the passion came of stroke and of community out You franchise DiaMedica XX at DMXXX. Genentech years the join for he
President late clinical a execution vast Senior trial trials experience Clinical of also and added time has Operations, under expertise budget. with reputation and in significant We completing Development operation Julie and planning clinical phase bringing Daves, on Vice for our
Chief Development the we includes officer, expertise. regulatory at positions announced addition, Chief us. Officer. Tanya Chief This joined that board In has as has and Quality Tanya Regulatory level, recently Lewis extensive global Officer
work has responsible the these hold DiaMedica and She has been the to for process regulatory been FDA. way involved a and individuals entire making It's team. other with their with privilege products several situations clinical the approval with through
morning, bring will you forward from this can getting with under and We of this important see this continue as bright stroke DMXXX to patients. to forward. the have we to hold we grow and As we treatment out tell a to the team move here horizon resuming development we built clinical look
DMXXX, I'd the rationale that point usage the a additional KLKX to an important KLKX current is China. of form protein and synthetic of in morning One this protein a for make developing like
the human from know, As form many of is of protein you in isolated KLKX urine. a China,
been That over Kallikrein for increase in medicines In XXX,XXX in in usage the and There has XXXX national was than called stroke patients a treating product XXXX, added reimbursement a patients China. decade more alone. now. to Kallikrein were list. dramatic is This for treated spurred
China. who the that treatment the our US recombinant form needed much knowledge the per more patients treatment today This gives and option. To a confidence X can put the not extensive KLKX's clinical that's therapy of and bring world this have in this year KLKX to approximately use XX% the do rest of of into us annual perspective, million for of estimated even the strokes
to now over turn like Scott Kellen the to highlights. to would the call financial I review
